lenalidomide

Lenalidomide (CC-5013) is an immunomodulator with oral activity. Lenalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN), which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase, and is commonly used in the synthesis of PROTAC products.

Lenalidomide-Br (Compound 41), a derivative of Lenalidomide, acts as a ligand for cereblon (CRBN) - an E3 ubiquitin ligase involved in protein recruitment. This compound can be conjugated to a protein ligand via a linker to create PROTACs, such as the PROTAC STAT3 degrader SD-36.

Lenalidomide-C4-NH2 hydrochloride is a Cereblon ligand derived from Lenalidomide. It serves as a recruiting agent for the CRBN protein. The compound, known as PROTAC (Compound 24), can be formed by linking Lenalidomide-C4-NH2 hydrochloride to the ligand for the protein. It exhibits inhibitory effects with IC50s of 0.98 nM and 13.7 nM against the growth of RS4;11 and MOLM-13 acute leukemia cell lines, respectively[1].

Lenalidomide-C5-NH2 is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-NH2 can be connected to the ligand for protein by a linker to form PROTACs[1].

Lenalidomide-acetylene-C5-COOH (compound 43; Cereblon ligand-linker Conjugate) is a Lenalidomide-based Cereblon ligand that facilitates CRBN protein recruitment and can be linked to the protein's ligand via a linker, forming a PROTAC[1].

Lenalidomide-C9-aldehyde is a synthesized E3 ligase ligand-linker conjugate that incorporates the Lenalidomide based cereblon ligand and a linker. Lenalidomide-C9-aldehyde can be used in the synthesis of a series of PROTACs, such as INY-03-041. INY-03-041

Lenalidomide-OH is an analog of Lenalidomide, a cereblon ligand for E3 ubiquitin ligase (CRBN), used for CRBN protein recruitment. It is able to attach to protein ligands using linkers to form PROTAC.

Lenalidomide-PEG1-azide is an E3 ligase ligand-linker conjugate that incorporates the cereblon ligand based on Lenalidomide and a linker. It is designed for use in the development of PROTAC BRD4 Degrader-2[1].

Lenalidomide-PEG3-iodine, an E3 ligase ligand-linker conjugate, consists of a cereblon-based Lenalidomide ligand and a 3-unit polyethylene glycol (PEG) linker. This compound is utilized in creating various proteolysis targeting chimeras (PROTACs), including the highly effective PROTAC BTK degrader SJF620, which has a degradation concentration 50 (DC50) of 7.9 nM[1].

Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride is a chemical compound comprising a cereblon (CRBN) ligand that functions as an E3 ubiquitin ligase, along with a linker. It is utilized to create the PROTAC MD-224[1].

Lenalidomide-propargyl-C2-NH2 hydrochloride is a compound that features a cereblon (CRBN) ligand for the E3 ubiquitin ligase, as well as a linker. It is utilized in the development of the PROTAC MD-224[1] system.

(3S)Lenalidomide-5-Pip-C-Pip-2C-Pip serves as an E3 Ligase Ligand-Linker Conjugate and is utilized in the synthesis of PROTAC Cbl-b-IN-1.

(3S)Lenalidomide-5-Br is a ligand for E3 ubiquitin ligases (Ligands for E3 Ligase). It is utilized in the synthesis of PROTACCbl-b-IN-1.

Lenalidomide-C13-piperazine-Boc is a conjugate of an E3 ligase ligand and linker used in synthesizing the PROTAC degrader NC-R17.

Lenalidomide-Pip-butyn is an E3 ligase ligand-linker conjugate based on Lenalidomide, designed for the recruitment of the CRBN protein. This compound can be attached to a protein ligand to form a PROTAC, such as the PROTAC STAT3 degrader SD-436.

Lenalidomide-ethyne-C2-Pip-CO-Pip (intermediate 3) is an E3 ubiquitin ligase ligand-linker conjugate. It serves as a precursor in the synthesis of QA-68.

(3S)Lenalidomide-piperazine-C-piperidine is an E3 ubiquitin ligase ligand-linker conjugate (E3 Ligase Ligand-Linker Conjugates). This compound can be utilized in the synthesis of PROTAC ER Degrader-11.

Lenalidomide-6-F-piperidine-C2-Pip-C-COOH acts as a linker and an E3 ligase ligand for PROTACBTKDegrader-5, utilized in the study of malignant lymphomas.

Lenalidomide-F serves as the E3 ligase ligand for LWY713. LWY713 is a PROTAC-based FLT3 degrader (DC50= 0.64 nM) that selectively induces the degradation of FLT3 through a cereblon and proteasome-dependent mechanism.

Lenalidomide-Glycolic acid is a conjugate of an E3 ligase ligand and a linker, used in the synthesis of the PROTAC-type FLT3 degrader LWY713.

Lenalidomide-hex-5-ynoic acid is a conjugate of an E3 ligase ligand and linker, utilized in the synthesis of PROTACs, such as PROTACcGAS degrader-1.

Lenalidomide hydrochloride (CC-5013 hydrochloride), a Thalidomide derivative, functions as molecular glue and serves as an orally active immunomodulator. As a ligand for the ubiquitin E3 ligase cereblon (CRBN), it facilitates the selective ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 through the CRBN-CRL4 ubiquitin ligase. Specifically, Lenalidomide hydrochloride inhibits the growth of mature B-cell lymphomas, including multiple myeloma, and promotes IL-2 release from T cells [1] [2].

Lenalidomide hemihydrate is a derivative of Thalidomide, an orally active immunomodulator that acts as a molecular gel. It is a ligand for the ubiquitin E3 ligase cereblon, which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase.

Functionalized cereblon ligand for PROTAC research and development; incorporates an E3 ligase ligand plus a PEG1 linker with terminal amine ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.